Investing.com - Opus Genetics (NASDAQ: IRD) reported second quarter EPS of $-0.120, $0.07 better than the analyst estimate of $-0.190. Revenue for the quarter came in at $2.88M versus the consensus estimate of $4.04M.
Opus Genetics’s stock price closed at $1.10. It is up 7.840% in the last 3 months and down -12.000% in the last 12 months.
Opus Genetics saw positive EPS revisions and negative EPS revisions in the last 90 days. See Opus Genetics’s stock price’s past reactions to earnings here.
According to InvestingPro, Opus Genetics’s Financial Health score is "fair performance".
Check out Opus Genetics’s recent earnings performance, and Opus Genetics’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
Opus Genetics earnings beat by $0.07, revenue fell short of estimates
Published 2 months ago
Aug 13, 2025 at 10:38 PM
Positive
Auto